ArticlePlastic and reconstructive surgery. Global open2026
Persistent Hyperpigmentation Following Coretox Injection: A Review of Adverse Events Associated with Polysorbate 20.
Article in Plastic and reconstructive surgery. Global open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Postprocedural hyperpigmentation is a rare but concerning complication after botulinum toxin type A injections. In 2024, 3 patients developed persistent facial hyperpigmentation following Coretox administration in the glabellar and forehead regions. This case series characterizes the clinical course, imaging findings, and hypothesized mechanisms underlying this reaction. Three female patients received Coretox injections using standard aesthetic techniques, including subdermal injections in the forehead and periorbital regions and intramuscular injections in the glabellar region. Serial clinical photographs and QuantifiCare LifeViz imaging-including cross-polarized, ultraviolet-filtered, and hemoglobin-filtered modes-were performed from baseline through follow-up. Medical histories, sun exposure, skincare routines, and concurrent medications were reviewed. No patients reported recent use of photosensitizers, active dermatitis, or excessive ultraviolet exposure. All 3 cases exhibited localized hyperpigmented macules at injection sites, appearing 2-3 weeks postprocedure. QuantifiCare imaging demonstrated elevated melanin and hemoglobin signal intensity in affected areas. Although pigmentation lightened slightly over 2-3 months, the discoloration persisted beyond 1 year in all cases as of October 2025. Exosome-based treatment, Rejuran injection, and laser therapies were attempted without significant improvement. Approximately 1,400 vials of Coretox have been used by the author since 2019, with all three pigmentation events linked to batch E622080A (June 28, 2024). This is the first report to document persistent facial hyperpigmentation following Coretox injection, using serial imaging analysis. Although the pathogenesis remains unclear, polysorbate 20-a stabilizer replacing human serum albumin-may act as a trigger in susceptible individuals. Early recognition, patient counseling, and photoprotection are recommended. Further investigation into excipient-induced pigmentary changes is warranted.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.